Time trends regarding the use of cardiovascular, renal, and diabetic evidence-based therapies among high-risk patients with type 2 diabetes mellitus (CRD-T2)

Type 2 diabetes mellitus (T2DM) affects 463 million people globally and is expected to affect 12.1% of Canadians by 2025. It can lead to complications, including cardiovascular disease and chronic kidney disease. High-risk patients with cardiovascular and renal co-morbidities have an increased risk of mortality. The DECIDE-CV, a cardiometabolic clinic. Staffed by three MDs  (cardiology, endocrinology and nephrology) and a nurse. Focuse on optimizing diabetes-vascular-renal therapies for high-risk patients with T2DM. The clinic. The study aims to analyze the use of cardiovascular, diabetic, and renal evidence-based treatments in DECIDE-CV clinic, compare data with other clinics, track patient demographics and outcomes, as well as determine their association with clinical outcomes.